Overview Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy Status: Recruiting Trial end date: 2022-06-01 Target enrollment: Participant gender: Summary The objective of this study is to evaluate the safety and efficacy of APX3330 to treat diabetic retinopathy (DR) and diabetic macular edema (DME). Phase: Phase 2 Details Lead Sponsor: Ocuphire Pharma, Inc.